Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (March 2021)
39 slides from Evogene's investor presentation, March 2021

Slide 1: Investor Presentation
INVESTOR PRESENTATION Ofer Haviv, President & CEO March 2021

Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or

Slide 3: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Addressing the discovery and development challenges of life science-based product Annex II - Financial Fundamentals 3

Slide 4: Our Vision: Decoding Biology
OUR VISION DECODING BIOLOGY Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. 4

Slide 5: Life-science product discovery & development challenges
Life-science product discovery & development challenges Low probability of success with high cost and long time-to-market Ag-chemicals Pharmaceutical Industry Industry Discovery and CDER’S* annual novel development costs drug approvals: of a new crop 2010-2019 protection product Source: Phillips McD

Slide 6: The opportunity
HUMAN HEALTH The opportunity Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & AGRICULTURE development. OTHER INDUSTRIES 6

Slide 7: When biology meets disruptive technologies
When biology meets disruptive technologies; introducing– platform BIOLOGY Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully BIG DATA AI discover & guide the development of novel life-science based products. Dev

Slide 8: Tailor-made Engines for product discovery & development
Tailor-made Engines for product discovery & MICROBES development The CPB platform enhances product discovery and development through dedicated Engines for products based on SMALL MOLECULES three core components: ▪ Microbes ▪ Small molecules ▪ Genetic elements GENETIC ELEMENTS 8

Slide 9: Tailor-made Engines for product development
Tailor-made Engines for product development MICROBES Discovery Computational selection of the most promising candidates to initiate the product development process. BIOLOGY SMALL MOLECULES Development BIG DATA AI Computational driven solution addressing optimization development challenges for the se

Slide 10: Business Model: Product development through collaborations
1 Business Model Product development through collaborations Joint development with leading companies for defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will likely be done by the partner. Potential revenue for Evogene • Licensing an

Slide 11: Business Model: Product development through subsidiaries
2 Business Model Product development through subsidiaries Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategi

Slide 12: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Addressing the discovery and development challenges of life science-based product Annex II - Financial Fundamentals 12

Slide 13: Potential fields of activity
Potential fields of activity OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES MICROBES SMALL MOLECULES GENETIC ELEMENTS 13

Slide 14: Current life-science based products under development
Current life-science based products under development OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES Microbiome MICROBES based Ag-Biologicals Therapeutics SMALL MOLECULES Drugs based on Ag-Chemicals small molecules GENETIC ELEMENTS Ag-solutions Medical Seed Traits for castor Cannabis oil production 14

Slide 15: Development & commercialization through subsidiaries and collaborations
Development & commercialization through subsidiaries and collaborations OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES MICROBES SMALL MOLECULES * GENETIC ELEMENTS Seed Traits [division] * non-exclusive license 15

Slide 16: Evogene Group – More to Come
Evogene Group – More to Come New activity We are now evaluating the initiation of discovery and development of new life- science based products in various new fields OTHER HUMAN HEALTH AGRICULTURE of activity. INDUSTRIES MICROBES Microbe for aquaculture* SMALL MOLECULES Drug optimization* GENETIC EL

Slide 17: Evogene Group
Evogene Group Human Other Health Agriculture Industries 90%* 100%* 98%* 72%* Internal division of Evogene 100%* Microbiome based Medical Cannabis Ag Chemicals Ag Biologicals Seed Traits Castor Oil Therapeutics Production • Immuno-oncology • High yield & consumer • Herbicides • Bio-Stimulants • Yield

Slide 18: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Addressing the discovery and development challenges of life science-based product Annex II - Financial Fundamentals 18

Slide 19: Human Microbiome: Mission, Product Pipeline
| Human Microbiome Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational biology. Product Pipeline: Expected main near-term value drivers: Immuno-oncology program: 2021 • Combination therapy for cancer with checkpoint inhibitors ▪ Inflammato

Slide 20: Human Microbiome: Example Results
| Human Microbiome Example Results: Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone 20

Slide 21: Medical Cannabis: Mission, Product Pipeline
| Medical Cannabis Mission: Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology. Product Pipeline: Expected main near-term value drivers: 2021 MetaYield Products: ▪ MetaYield - reach 1st commercial variety; sign distribution agreements

Slide 22: Medical Cannabis: Example Results
| Medical Cannabis Example Results: MetaYield products under development – increased compounds per area, addressing the T20/C4 (THC 16%- 24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market Medical Cannabis aiming at high THC, high yield, big infl

Slide 23: Ag-Chemicals: Mission, Product Pipeline
| Ag-Chemicals Mission: Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry. Product Pipeline: Expected main near-term value drivers: Herbicides: 2021 • Novel MoA (Mode-of-Action) selective/non-selective ▪ New MoA Herb

Slide 24: Ag-Chemicals: Example Results
| Ag-Chemicals Example Results: Leading novel MoA herbicide candidate – displaying efficacy in eradicating multiple important weed species in field tests (weed) Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 24

Slide 25: Ag-Biologicals: Mission, Product Pipeline
| Ag-Biologicals Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology. Product Pipeline: Expected main near-term value drivers: Bio-stimulants (live microbials for yield 2021 improv

Slide 26: Ag-Biologicals: Example Results
| Ag-Biologicals Example of treatment with LAV312 against Botrytis Cinerea in vines – untreated control vs treated vines Lavie Bio’s wheat field in the USA during harvest 26

Slide 27: Subsidiaries - expected main near-term value drivers
Subsidiaries - expected main near-term value drivers 2021 2022 Immuno-oncology - Inflammatory Bowel IBD - initiate first GMP Immuno-oncology - initiate proof of Disease (IBD) - extend production of drug readout from proof of concept, first in man pre-clinical study candidates for IBD concept, first

Slide 28: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Addressing the discovery and development challenges of life science-based product Annex II - Financial Fundamentals 28

Slide 29: Summary
Summary Our vision - Revolutionizing life-science based product Dual based business model - utilizing Evogene’s solutions for: discovery & development, utilizing cutting edge computational 1. Product development & commercialization through collaborations biology technologies. 2. Product development

Slide 30: Thank You
+ THANK YOU! evOgene ' be

Slide 31: Annex I: Addressing the discovery and development challenges of life science-based product
Annex I: Addressing the discovery and development challenges of life science-based product 31

Slide 32: The challenge in creating life-science based products
The challenge in creating life-science based products Discovery Development Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 32

Slide 33: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 33

Slide 34: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Development – inefficient optimization & difficulty in addressing a single challenge without impairing others Low probability of success Long time to market Hi

Slide 35: Evogene's AI-based solution: Discovery
Evogene’s AI-based solution: Discovery A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 35

Slide 36: Evogene's AI-based solution: Development
Evogene’s AI-based solution: Development A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definiti

Slide 37: Evogene's AI engines provide tailor-made solutions
Evogene’s AI engines provide tailor-made solutions Discovery Computational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes. Development Computational driven solution for guiding and assessing the optimization process of the selected core

Slide 38: Annex II: Financial Fundamentals
Annex II: Financial Fundamentals 38

Slide 39: Key Financials: Balance Sheet
Key Financials: Thousands of US $ 31.12.2020 31.12.2019 Balance Sheet Current Assets 51,823 49,027 Long-Term Assets 20,092 22,337 Total Assets 71,915 71,364 Current Liabilities 9,676 5,746 Key Points: • Consolidated cash position: ~$48.2 million as of Long-Term Liabilities 5,357 5,401 31.12.2020, ~$
Source: Internet Archive copy of evogene.com
More decks from Evogene Ltd.
Investor Presentation (August 2026)32 slides · Aug 27, 2026
Q2 2026 Earnings Presentation18 slides · Aug 18, 2026
Investor Presentation (June 2026)32 slides · Jun 16, 2026
Q1 2026 Earnings Presentation27 slides · May 20, 2026
Investor Presentation (April 2026)27 slides · Apr 28, 2026
Investor Presentation (March 2026)26 slides · Mar 12, 2026